||Chikungunya Virus Antibodies, IgM
||Arbovirus, Chikungunya virus serology
||Test performed Monday-Friday ; Turn-around time 7 days
||Serum and cerebrospinal fluid (CSF)
| Collection Device:
||Clot (Red) or SST(Gold) tube
CSF collection tube
Specimen Labeling: Test subject to CLIA regulations and require 2 patient identifiers on specimen container and requisition forms.
||Serum: 1 mL (minimum:0.5 mL). Additional testing for Zika and dengue requires separate containers.
CSF: 1.0 mL
||Centrifuge and aliquot serum into sterile leak-proof tube, ASAP. Place both CSF and serum at 4°C.
Shipping instructions, including specimen handling requirements during transport: Sender should contact the NPHL by email or phone before shipping. Ship specimen Monday -Thursday overnight to avoid weekend deliveries. Refrigerated, specimen should be shipped on cold packs. Package and ship as Category B, Biological Substance, UN3373. See instructions and shipping address: http://nphl.org/. Do not send directly to CDC.
||Severely lipemic, icteric or hemolyzed samples; heat-inactivated serum; multiple freeze thaw cycles
| Specimen Stability:
||2-8 °C for 72 hours, if > 3 days, freeze
| Reference Interval:
||Negative – No significant level of detectable chikungunya virus IgM antibody.
Equivocal – Questionable presence of antibodies. Repeat testing in 10-14 days may be helpful.
Positive – IgM antibody to chikungunya virus detected, which may indicate a current or past infection.
| Reportable Disease:
||A positive result is reportable as Arbovirus infection under Title 173, report within 7 days
||Pre-approval needed from state or local health department. Local or State Health Department. Send approval to NPHL@unmc.edu or call (402) 559-9444.
Supplemental Forms Required - NPHL Special Microbiology Requisition must accompany the specimen to include the following information: symptoms and date of onset, pregnancy status, travel and vaccine history.
Virus-specific IgM antibodies may be detectable >3 days after onset of illness. However, serum collected within 7 days of illness onset may not have detectable virus-specific IgM antibodies and IgM testing should be repeated on a convalescent-phase sample to rule out infection in patients with a compatible clinical syndrome.